December 07, 2004

Developing SZ drugs with new mechanism

Novasite Pharmaceuticals and the Stanley Medical Research Institute are teaming up to develop a new class of medications for schizophrenia and bipolar disorder.

Called "allosteric modulator drugs", these compounds act at a regulatory site in brain receptors, different from the site that target neurotransmitters use.

According to the press release, allosteric drugs may be a safer option because they mimic the behavior of natural regulatory molecules in the body. This more natural mechanism of action may prevent potential overdose, tolerance, abuse, and dependence problems.

View the press release: "Novasite Pharmaceuticals and the Stanley Medical Research Institute Announce Alliance to Discover Novel Allosteric Modulator Drugs for Schizophrenia" (12/6/04). Available at


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required